BHST

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Tuesday that Olive Cell, an olive-derived plant-cell ingredient, is ready for commercial licensing, the second product from its Botanical Synthesis technology to reach that stage.  The company said Olive Cell has completed large-scale bioreactor scale-up, manufacturing readiness and a self-affirmed U.S. Generally Recognized as Safe (GRAS) process.

Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization High-potency proprietary olive-derived Verbascoside composition demonstrates promising dose-dependent preclinical activity across liver steatosis and fibrosis models, with potential for development across multiple health and wellness categories Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ technology, today announced that its proprietary Olive Cell composition (Olive Cell) has reached commercial readiness and is now available for licensing and commercialization through the Company's CDMO business. This milestone marks the completion of BioHarvest's development pathway for Olive Cell - from plant-cell development and optimization through large-scale bioreactor scale-up, commercial manufacturing readiness and completion of the applicable self-affirmed U.S. Generally Recognized as Safe ("GRAS") process.

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday its Botanical Synthesis platform can produce the next-generation sweetener targeted in its joint development program with Tate & Lyle.  Tate & Lyle, a supplier of ingredient solutions for food and beverages, is looking to broaden its range of sweeteners as manufacturers seek ways to cut sugar and calories without losing taste and functionality, the companies said.

Progress demonstrates that BioHarvest's Botanical Synthesis(TM) platform is capable of producing the targeted next-generation sweetening solution Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme. The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted next-generation sweetening solution.

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said Tuesday its board has authorized a share repurchase program covering up to 5% of its outstanding common shares.  The company, which develops and manufactures proprietary plant-based compositions for customers, partners and its own portfolio, will structure the program as a normal course issuer bid, in line with Canadian practice.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers, partners and its own portfolio, announced today that its Board of Directors has authorized a share repurchase program, structured in accordance with Canadian practices as a normal course issuer bid (the "NCIB"). The Company's Board of Directors believes that the market price of the Common Shares may not fully reflect the underlying value of the Company's business and future growth prospects.

Single-dose VINIA Daily Chews broaden demographics and usage occasions while demonstrating the commercial versatility of Botanical Synthesis Format expansion shows how BioHarvest can help CDMO partners move from plant-cell compositions to differentiated consumer products Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 15, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers and its own portfolio, today announced the launch of single-dose VINIA® Daily Chews. The new delivery format is designed to expand the addressable market for VINIA and to further demonstrate BioHarvest's progress toward leadership in industrial-scale Botanical Synthesis, the platform behind the Company's approach to consistent, full-spectrum plant compounds at scale.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026, in New York City, NY.

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) plans to pursue a dual listing of its ordinary shares on the Tel Aviv Stock Exchange (TASE), with trading expected to begin on September 8, 2026. The company, which is listed on the Nasdaq Capital Market, expects the TASE listing to provide investors in Israel with access to its shares.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets. BioHarvest expects its shares to begin trading on the TASE on September 8, 2026.